Nasus Pharma (NSRX) Company presentation summary

Strategic positioning and technology

• Proprietary Nasax powder technology enhances intranasal drug absorption, targeting rapid and precise delivery for emergency indications.

• Lead product NS002 is a needle-free, easy-to-administer alternative to injectable epinephrine, addressing limitations of autoinjectors.

• Platform uses well-known APIs, enabling a lower-risk 505(b)(2) regulatory pathway.

• Robust global IP portfolio with patents granted or in progress through at least 2038.

• Strong financial position supports ongoing clinical development and pipeline expansion.

Clinical pipeline and development

• NS002 (intranasal epinephrine) is in Phase 2, with pivotal trial initiation expected Q4 2026.

• Additional pipeline includes NS003 (ondansetron, preclinical), NS004 (metabolic, preclinical), NS005 (cardiovascular, preclinical), and NS001 (naloxone, pivotal Phase 3 completed).

• NS001 (intranasal naloxone) demonstrated faster and higher absorption than Narcan in Phase 3, validating the platform.

• Multiple assets are available for partnering.

Market opportunity and competitive landscape

• Anaphylaxis affects 1–3% of the global population; the epinephrine market is valued at $2.3B (2024) with 6.5% CAGR.

• Up to 50% of at-risk patients do not carry or refill epinephrine, highlighting unmet need.

• Needle-free epinephrine products could significantly expand market reach.

• NS002 shows favorable pharmacokinetics compared to EpiPen and other competitors, with faster onset and higher absorption.